文献速递肿瘤 PET/CT神经核医学

[18F]mFBG PET-CT用于神经母细胞瘤的检测与定位:一项前瞻性先导研究

[18F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-12-12

这项前瞻性单中心先导研究纳入14例神经母细胞瘤患儿,在[123I]mIBG扫描后两周内行[18F]mFBG PET-CT(2 MBq/kg),比较配对扫描的肿瘤定位。结果显示[18F]mFBG PET-CT耐受良好、无相关不良事件,扫描时间显著短于[123I]mIBG,且检出更多软组织病灶和更高SIOPEN评分,提示其用于神经母细胞瘤成像可行。

要点

  • [18F]mFBG PET-CT平均扫描时间9.0分钟(SD 1.9),显著短于[123I]mIBG扫描的84.5分钟(SD 10.5),p<0.01。
  • 相比[123I]mIBG扫描,[18F]mFBG PET-CT在40%扫描对中检出更多软组织病灶,55%相等,5%更少。
  • 每例患者平均多检出2个软组织病灶,SIOPEN评分平均高6分。

核心结论

  • 本研究结果证明[18F]mFBG PET-CT用于神经母细胞瘤成像具有可行性。
  • 相比[123I]mIBG扫描,[18F]mFBG PET-CT检出更多神经母细胞瘤定位。
  • [18F]mFBG PET-CT在未来的神经母细胞瘤分期和疗效评估中有望应用。

研究设计与样本

  • 前瞻性单中心先导研究,招募因神经母细胞瘤转诊行[123I]mIBG扫描的儿童患者。
  • 共14例患者(中位年龄4.9岁,13例为4期疾病,1例为4S期),完成20对[123I]mIBG与[18F]mFBG扫描。
  • [123I]mIBG扫描包括全身平面闪烁显像联合SPECT-CT;[18F]mFBG PET-CT在注射2 MBq/kg后1小时和2小时行全身扫描。
  • 比较扫描对检出的肿瘤定位,软组织病变按病灶数量量化,骨骼病变按SIOPEN评分量化。

主要发现

  • [18F]mFBG注射耐受良好,所有患者均未发生相关不良事件。
  • [18F]mFBG PET-CT平均扫描时间9.0分钟(SD 1.9),显著短于[123I]mIBG扫描的84.5分钟(SD 10.5),p<0.01。
  • 大多数肿瘤定位在注射后1小时较2小时的[18F]mFBG PET-CT上检出。
  • 相比[123I]mIBG扫描,[18F]mFBG PET-CT在40%扫描对中检出更多软组织病灶、55%相等、5%更少。
  • 相比[123I]mIBG扫描,[18F]mFBG PET-CT在55%扫描对中SIOPEN评分更高、30%相等、15%更低;每例患者平均多检出2个软组织病灶、SIOPEN评分平均高6分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Meta-[18F]fluorobenzylguanidine ([18F]mFBG) is a positron emission tomography (PET) radiotracer that allows for fast and high-resolution imaging of tumours expressing the norepinephrine transporter. This pilot study investigates the feasibility of [18F]mFBG PET-CT for imaging in neuroblastoma. METHODS: In a prospective, single-centre study, we recruited children with neuroblastoma, referred for meta-[123I]iodobenzylguanidine ([123I]mIBG) scanning, consisting of total body planar scintigraphy in combination with single-photon emission computed tomography-CT (SPECT-CT). Within two weeks of [123I]mIBG scanning, total body PET-CTs were performed at 1 h and 2 h after injection of [18F]mFBG (2 MBq/kg). Detected tumour localisations on scan pairs were compared. Soft tissue disease was quantified by number of lesions and skeletal disease by SIOPEN score. RESULTS: Twenty paired [123I]mIBG and [18F]mFBG scans were performed in 14 patients (median age 4.9 years, n = 13 stage 4 disease and n = 1 stage 4S). [18F]mFBG injection was well tolerated and no related adverse events occurred in any of the patients. Mean scan time for [18F]mFBG PET-CT (9.0 min, SD 1.9) was significantly shorter than for [123I]mIBG scanning (84.5 min, SD 10.5), p < 0.01. Most tumour localisations were detected on the 1 h versus 2 h post-injection [18F]mFBG PET-CT. Compared to [123I]mIBG scanning, [18F]mFBG PET-CT detected a higher, equal, and lower number of soft tissue lesions in 40%, 55%, and 5% of scan pairs, respectively, and a higher, equal, and lower SIOPEN score in 55%, 30%, and 15% of scan pairs, respectively. On average, two more soft tissue lesions and a 6-point higher SIOPEN score were detected per patient on [18F]mFBG PET-CT compared to [123I]mIBG scanning. CONCLUSION: Results of this study demonstrate feasibility of [18F]mFBG PET-CT for neuroblastoma imaging. More neuroblastoma localisations were detected on [18F]mFBG PET-CT compared to [123I]mIBG scanning. [18F]mFBG PET-CT shows promise for future staging and response assessment in neuroblastoma. TRIAL REGISTRATION: Dutch Trial Register NL8152.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Samim A, Blom T, Poot AJ, et al. [18F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2022. PMID: 36504277. doi:10.1007/s00259-022-06063-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。